LYEL (STOCKS)
Lyell Immunopharma, Inc. Common Stock
$13.550000
+0.050000 (+0.37%)
Prev close: $13.500000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Lynn Seely
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $316.53M
- Employees
- 300
- P/E (TTM)
- -1.06
- P/B (TTM)
- 1.15
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.10 | $-2.41 | +1.3123 | +54.40% |
|
Dec 2025 (Q4)
|
$-7.50 | $-2.28 | -5.2240 | -229.53% |
|
Sep 2025 (Q3)
|
$-2.13 | $-2.70 | +0.5654 | +20.98% |
|
Jun 2025 (Q2)
|
$-2.89 | $-3.66 | +0.7650 | +20.93% |
Financial Statements
| Revenues | $31.00K |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $256.33M |
| Nonoperating Income/Loss | $9.89M |
| Operating Expenses | $256.33M |
| Operating Income/Loss | -$256.30M |
| Income/Loss From Continuing Operations After Tax | -$246.41M |
| Income/Loss From Continuing Operations Before Tax | $31.00K |
| Net Income/Loss | -$246.41M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$246.41M |
| Net Income/Loss Available To Common Stockholders, Basic | -$246.41M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$13.80 |
| Diluted Earnings Per Share | -$13.80 |
| Basic Average Shares | 56,078,000 |
| Diluted Average Shares | 56,078,000 |
| Assets | $350.63M |
| Current Assets | $267.30M |
| Noncurrent Assets | $83.32M |
| Fixed Assets | $32.72M |
| Other Non-current Assets | $50.60M |
| Liabilities | $76.96M |
| Current Liabilities | $36.95M |
| Accounts Payable | $5.47M |
| Other Current Liabilities | $31.48M |
| Noncurrent Liabilities | $40.01M |
| Equity | $273.67M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $273.67M |
| Liabilities And Equity | $350.63M |
| Net Cash Flow From Operating Activities | -$133.80M |
| Net Cash Flow From Operating Activities, Continuing | -$133.80M |
| Net Cash Flow From Investing Activities | $2.01M |
| Net Cash Flow From Investing Activities, Continuing | $2.01M |
| Net Cash Flow From Financing Activities | $102.13M |
| Net Cash Flow From Financing Activities, Continuing | $102.13M |
| Net Cash Flow | -$29.66M |
| Net Cash Flow, Continuing | -$29.66M |
| Comprehensive Income/Loss | -$246.57M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$246.57M |
| Other Comprehensive Income/Loss | -$24.32M |